Anzeige
Mehr »
Freitag, 20.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N38G | ISIN: US29772L1089 | Ticker-Symbol:
NASDAQ
19.03.26 | 20:59
20,715 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ETON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ETON PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ETON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEton Pharmaceuticals: EPS übertrifft Schätzungen um 0,01 $ - Umsatz schlechter als erwartet7
DoEton Pharmaceuticals, Inc. - 10-K, Annual Report1
DoEton Pharmaceuticals, Inc. - 8-K, Current Report2
ETON PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoEton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results46Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS...
► Artikel lesen
MiEton Pharmaceuticals Q4 2025 Earnings Preview4
06.03.Eton Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
04.03.Eton Pharma Acquires U.S. Commercialization Rights For Hemangeol In Infantile Hemangioma-
03.03.Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 20262
02.03.Eton Pharmaceuticals acquires U.S. rights to hemangioma drug1
02.03.Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL (propranolol hydrochloride) Oral Solution221HEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company's Eton Cares patient...
► Artikel lesen
27.02.Weekly Buzz: MacroGenics' LINNET Trial On Hold; Eton Pharmaceuticals, Allurion Technologies Get FDA Nod; Gilead Sciences Snaps Up Arcellx869FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results...
► Artikel lesen
25.02.Eton Pharmaceuticals, Inc. - 8-K, Current Report1
25.02.FDA-Zulassung für DESMODA: Eton Pharmaceuticals zielt auf Markt für Diabetes insipidus1
25.02.Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA (desmopressin acetate) Oral Solution754DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing...
► Artikel lesen
02.02.Lizenz-Deal für Medikament beflügelt Eton Pharmaceuticals-Aktie2
02.02.Eton Pharmaceuticals lizenziert Wirkstoffkandidaten für extrem seltene Krankheit1
02.02.Eton Pharmaceuticals, Inc. - 8-K, Current Report2
02.02.Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate236Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq:...
► Artikel lesen
04.12.25Eton Pharmaceuticals, Inc. - 8-K, Current Report-
19.11.25Eton Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1